- Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
-
Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D
- KMID: 2404016
- J Gynecol Oncol.
- 2018 Mar;29(2):e21.
- doi: 10.3802/jgo.2018.29.e21
OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking.... -
- CITED
-
- Close
- SHARE
-
- Close
- TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
-
Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D
- KMID: 2537895
- J Gynecol Oncol.
- 2022 Jul;33(4):e50.
- doi: 10.3802/jgo.2022.33.e50
Objective Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of... -
- CITED
-
- Close
- SHARE
-
- Close
